Astrazeneca Regulatory News (AZN)

26 January 2021 15:00 GMT

Block listing application

A block listing application has been made for 5,000,000 Ordinary Shares of $0.25 each in AstraZeneca PLC (the "Company") to be admitted to the Official List of the Financial Conduct Authority and admitted to trading on the London Stock Exchange.

Admission is expected to become effective on 29 January 2021.

Upon issue, the shares will be fully paid and will rank pari passu in all respects with the existing ordinary shares of the Company and will be issued pursuant to the following employee share plans:

AstraZeneca Share Option Plan

AstraZeneca Savings-Related Share Option Plan

AstraZeneca All-Employee Share Plan

AstraZeneca PLC 2012 Savings-Related Share Option Scheme

AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.

Contacts

For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

Adrian KempCompany Secretary

AstraZeneca PLC